- Home
- EYE vs NVCR Comparison
EYE vs NVCR Comparison
Compare EYE & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EYE | NVCR |
|---|---|---|
| Founded | 1990 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2017 | 2015 |
Fundamental Metrics
Financial Performance| Metric | EYE | NVCR |
|---|---|---|
| Price | $17.61 | $14.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 6 |
| Target Price | ★ $31.22 | $28.08 |
| AVG Volume (30 Days) | ★ 2.4M | 1.6M |
| Earning Date | 05-13-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 202.78 | 21.79 |
| EPS | ★ 0.38 | N/A |
| Revenue | ★ $1,987,488,000.00 | $655,353,000.00 |
| Revenue This Year | $5.56 | $7.72 |
| Revenue Next Year | $6.58 | $6.74 |
| P/E Ratio | $44.16 | ★ N/A |
| Revenue Growth | ★ 9.00 | 8.28 |
| 52 Week Low | $14.75 | $9.82 |
| 52 Week High | $30.02 | $18.92 |
Technical Indicators
Market Signals| Indicator | EYE | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 48.11 | 42.22 |
| Support Level | $14.84 | $12.66 |
| Resistance Level | $29.56 | $15.46 |
| Average True Range (ATR) | 1.00 | 1.00 |
| MACD | 0.26 | -0.45 |
| Stochastic Oscillator | 60.94 | 27.62 |
Price Performance
Historical ComparisonAbout EYE National Vision Holdings Inc.
National Vision Holdings Inc. is an optical retailer in the United States. Its product portfolio includes eyeglasses, sunglasses, contact lenses, accessories, and other related products. The company operates through a single operating segment. The Owned and Host segment includes the company-owned brands America's Best and Eyeglass World. In America's Best stores, vision care services are provided by optometrists or by independent professional corporations. The Host segment consists of Military and Fred Meyer locations, where eye exams are provided by independent optometrists.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.